[Leflunomide in the treatment of rheumatoid arthritis].
Leflunomide is a new second-line drug for rheumatoid arthritis. This compound with long half-life inhibits proliferation of activated T lymphocytes. Phase III studies have demonstrated a clinical efficacy superior to placebo and identical to comparators (salazopyrine, methotrexate) with a faster onset of response. Improvement of inflammatory paramaters and functional capacity (HAQ) were observed as well as slowing of structural damage evaluated by X-rays. Global tolerance is fair, but possibility of hepatic involvement, although unfrequent, needs a regular survey.
Wendling
Daniel
D
Service de Rhumatologie, Hôpital Jean-Minjoz, CHU, 1, boulevard Alexander-Fleming, 25030 Besançon Cedex, France. daniel.wendling@ufc-chu.univ-fcomte.fr
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D007555:Isoxazoles / Q000627:therapeutic use*; D000077339:Leflunomide; D008875:Middle Aged; D011817:Rabbits; D051381:Rats; D013601:T-Lymphocytes / Q000187:drug effects
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007555:Isoxazoles; D000077339:Leflunomide